Advanced search
Publication Cover
Acta Cardiologica Volume 77, 2022 - Issue 1
Submit an article Journal homepage
112
Views
2
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Practice and long-term outcome of unprotected left main PCI: real-world data from a nationwide registry

Peter Kayaerta Department of Cardiology, Universitair Ziekenhuis Gent, Ghent, BelgiumCorrespondence[email protected]
,
Mathieu Coemanb Department of Cardiology, Jan Yperman Ziekenhuis, Ypres, Belgium
,
Claude Hanetc Department of Cardiology, Clinique Universitaire de l’université catholique de Louvain, Namur, Belgium
,
Marc J. Claeysd Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium;e Department of Cardiovascular Diseases, University of Antwerp, Antwerp, Belgium
,
Walter Desmetf Department of Cardiovascular Diseases, University Hospital Leuven, Leuven, Belgium
,
Michel De Pauwa Department of Cardiology, Universitair Ziekenhuis Gent, Ghent, BelgiumORCID Iconhttps://orcid.org/0000-0001-7697-3931
ORCID Icon,
Steven Hained Department of Cardiology, Antwerp University Hospital, Antwerp, Belgium;e Department of Cardiovascular Diseases, University of Antwerp, Antwerp, BelgiumORCID Iconhttps://orcid.org/0000-0003-3065-3443
ORCID Icon &
Yves Taeymansa Department of Cardiology, Universitair Ziekenhuis Gent, Ghent, Belgium
 show all
Pages 51-58 | Received 20 Dec 2020, Accepted 10 Jan 2021, Published online: 08 Mar 2021

References

  • Hanet C, Claeys MJ, Carlier M, et al. Quality assessment in percutaneous coronary interventions: the QERMID Belgian PCI registry. Acta Cardiol. 2017;73(4):388–391.
  • Kolh P, Windecker S, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46(4):517–592.
  • Cerci RJ, Arbab-Zadeh A, George RT, et al. Aligning coronary anatomy and myocardial perfusion territories: an algorithm for the CORE320 multicenter study. Circ Cardiovasc Imaging. 2012;5(5):587–595.
  • Neumann F-J, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018;40(2):87–165.
  • Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–1516.
  • Hachamovitch R, Hayes SW, Friedman JD, et al. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation. 2003;107(23):2900–2907.
  • Hachamovitch R, Rozanski A, Shaw LJ, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32(8):1012–1024.
  • Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117(10):1283–1291.
  • Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344(8922):563–570.
  • Rab T, Sheiban I, Louvard Y, et al. Current interventions for the left main bifurcation. JACC Cardiovasc Interv. 2017;10(9):849–865.
  • Stone GW, Sabik JF, Serruys PW, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med. 2016;375(23):2223–2235.
  • Mäkikallio T, Holm NR, Lindsay M, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet. 2016;388(10061):2743–2752.
  • Mangiacapra F, Maeng M, Cayla G, et al. EXCEL and NOBLE: stents or surgery for left main stem stenosis? EuroIntervention. 2017;13(5):e604–e608.
  • Silber S, Albertsson P, Avilés FF, et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J. 2005;26(8):804–847.
  • Thuijs DJFM, Kappetein AP, Serruys PW, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet. 2019;394(10206):1325–1334.
  • Holm NR, Mäkikallio T, Lindsay MM, et al. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet. 2020;395(10219):191–199.
  • Park D-W, Ahn J-M, Park H, et al. Ten-year outcomes after drug-eluting stents versus coronary artery bypass grafting for left main coronary disease: extended follow-up of the PRECOMBAT trial. Circulation. 2020;141(18):1437–1410.
  • Park DW, Ahn JM, Yun SC, et al. 10-year outcomes of stents versus coronary artery bypass grafting for left main coronary artery disease. J Am Coll Cardiol. 2018;72(23 Pt A):2813–2822.
  • Gallo M, Blitzer D, Laforgia PL, et al. Percutaneous coronary intervention versus coronary artery bypass graft for left main coronary artery disease: a meta-analysis. J Thorac Cardiovasc Surg. 2020. doi:https://doi.org/10.1016/j.jtcvs.2020.04.010
  • Ahmad Y, Howard JP, Arnold AD, et al. Mortality after drug-eluting stents vs. coronary artery bypass grafting for left main coronary artery disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2020;41(34):3228–3235.
  • Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis of the national cardiovascular data registry research to practice initiative. JAMA Cardiol. 2019;4(2):100–109.
  • Aminian A, Iglesias JF, Van Mieghem C, et al. First prospective multicenter experience with the 7 French Glidesheath slender for complex transradial coronary interventions. Catheter Cardiovasc Interv. 2017;89(6):1014–1020.
  • Colletti G, Auslender J, Dm A, et al. Feasibility and safety of performing complex coronary interventions by distal radial artery using the railway sheathless vascular system. J Invasive Cardiol. 2017;32(12):459–462.
  • Head SJ, Milojevic M, Daemen J, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018;391(10124):939–948.
  • Kinnaird T, Gallagher S, Anderson R, et al. Are higher operator volumes for unprotected left main stem percutaneous coronary intervention associated with improved patient outcomes? Circ: Cardiovasc Interventions. 2020;13(6):1–10.
  • Xu B, Redfors B, Yang Y, et al. Impact of operator experience and volume on outcomes after left main coronary artery percutaneous coronary intervention. JACC Cardiovasc Interv. 2016;9(20):2086–2093.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.